Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from SciSparc Ltd. ( (SPRC) ) is now available.
On July 30, 2025, SciSparc Ltd. announced the filing of an international patent application in collaboration with Clearmind Medicine Inc. for a novel combination therapy targeting weight loss and fatty liver disease. This development aims to address global health challenges such as obesity and metabolic dysfunction-associated steatotic liver disease. Additionally, SciSparc announced updates on a proposed merger with AutoMax Motors Ltd., with the SEC declaring the Form F-4 Registration Statement effective. The company also extended the deadline for entering definitive agreements with Miza III Ventures Inc. to October 15, 2025, with the transaction expected to close by October 31, 2025.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 110,782
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
For an in-depth examination of SPRC stock, go to TipRanks’ Overview page.